T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04

被引：0
|
作者：
Tsurutani, Junji [1 ]
Modi, Shanu [2 ]
Sohn, Joo Hyuk [3 ]
Tokunaga, Eriko [4 ]
Niikura, Naoki [5 ]
Park, Yeon Hee [6 ]
Lee, Keun Seok [7 ]
Chae, Yee Soo [8 ]
Wang, Xiaojia [9 ,10 ]
Li, Wei [11 ]
Im, Seock-Ah [12 ]
Xu, Binghe [13 ]
Lu, Yen-Shen [14 ]
Gambhire, Dhiraj [15 ]
Nishijima, Soichiro [16 ]
Nishiyama, Yuji [16 ]
Sugihara, Masahiro [16 ,17 ]
机构：
[1] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Yonsei Canc Ctr, Seoul, South Korea
[4] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[5] Tokai Univ, Hiratsuka, Kanagawa, Japan
[6] Samsung Med Ctr, Seoul, South Korea
[7] Natl Canc Ctr, Gyeonggi Do, South Korea
[8] Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea
[9] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[10] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
[11] 1st Hosp Jilin Univ, Changchun, Peoples R China
[12] Seoul Natl Univ Hosp, Seoul, South Korea
[13] CAMS, Canc Inst & Hosp, Beijing, Peoples R China
[14] Natl Taiwan Univ Hosp, Taipei, Taiwan
[15] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[16] Daiichi Sankyo Co Ltd, Tokyo, Japan
[17] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2-2
引用
收藏
页码：S1379 / S1379
页数：1
相关论文
共 50 条
  • [21] T-DXd for HER2-low expressing cases breast cancer at our hospital
    Noguchi, E.
    Shimizu, Y.
    Nogami, M.
    Tsukada, H.
    Natori, K.
    Aoyama, K.
    Akashi-Tanaka, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1395 - S1395
  • [22] Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
    Hu, X.
    Curigliano, G.
    Yonemori, K.
    Bardia, A.
    Barrios, C. H. E.
    Sohn, J.
    Levy, C.
    Jacot, W.
    Tsurutani, J.
    Mezei, K.
    de Climens, A. Roborel
    Wu, X.
    Begbie, N.
    Mbanya, Z.
    Dent, R. A.
    ANNALS OF ONCOLOGY, 2024, 35 : 1214 - 1215
  • [23] Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
    Zhan, Mei
    Huang, Zijia
    Xu, Ting
    Xu, Xinyi
    Zheng, Hanrui
    Wu, Fengbo
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [24] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer
    Fessler, Beate
    BREAST CARE, 2023, 18 (02)
  • [26] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
    Modi, Shanu
    FUTURE ONCOLOGY, 2025, 21 (04) : 367 - 380
  • [27] Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Ueno, N. T.
    Niikura, N.
    Yamashita, T.
    Jacot, W.
    Cameron, D. A.
    Tsurutani, J.
    Sohn, J.
    Tokunaga, E.
    Vidal Losada, M. J.
    Park, Y. H.
    Lee, K. S.
    Chae, Y. S.
    Prat, A.
    Suto, F.
    Kuwahara, Y.
    Boran, A. D.
    Kobayashi, M.
    Kumar, V.
    Aguilar, C. Orbegoso
    Modi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S401 - S402
  • [28] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Liu, Yali
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Baselga, Jose
    Krop, Ian E.
    CANCER RESEARCH, 2021, 81 (04)
  • [29] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2+mBC
    Andre, Fabrice
    Hamilton, Erika P.
    Loi, Sherene
    Anders, Carey K.
    Schmid, Peter
    Stroyakovskiy, Daniil
    Villanueva, Rafael
    Pedrini, Jose Luiz
    Doval, Dinesh Chandra
    Zurawski, Bogdan
    Chen, Shin-Cheh
    Boston, Sarice Renee
    Konpa, Adam
    Pierotti, Barbara
    Fabbri, Giulia
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345